Antonio C. Wolff and Mikala Egeblad were named co-directors of the Breast and Gynecologic Cancer Program at Johns Hopkins Kimmel Cancer Center.
Wolff and Egeblad will lead a multidisciplinary faculty team including colleagues in gynecologic oncology, medical oncology, surgical oncology, pathology, radiation oncology, radiology, and basic sciences across the university.
The program aims to support multi-project grants, cross-disciplinary research, education and mentorship, and expanding patient access at all Kimmel locations: Viragh Clinic in Baltimore, the Greater Washington Area, Green Spring Station, and Bayview.
Wolff is a professor of oncology at John Hopkins, who works on breast cancer biomarkers, including HER2. His work has focused on improving the quality of HER2 testing in breast cancer.
Wolff is a Komen Scholar and BCRF investigator. He recently served as associate editor for Journal of Clinical Oncology, and now serves on the National Comprehensive Cancer Network Guideline Steering Committee.
As a leader of the Translational Breast Cancer Research Consortium, Wolff is one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy.
After serving as chair of the Breast Committee at ECOG-ACRIN, he was elected co-chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative.
Egeblad joined Johns Hopkins University as a Bloomberg Distinguished Professor in 2023 from Cold Spring Harbor Laboratory.
She studies how the tumor microenvironment regulates cancer initiation, progression, and metastasis. A current line of research involves learning more about how the brain regulates the immune system to combat cancer.
Egeblad serves as associate director of the Giovanis Institute for Translational Cell Biology, co-leader of the Kimmel Cancer Center’s Cancer Invasion and Metastasis Program, and is part of the Kimmel Cancer Center’s Convergence Institute.
She was most recently elected to the AACR board of directors for the 2025-2028 term.
